Benitec Biopharma (BNTC) Projected to Release Quarterly Earnings on Monday

Key Points

• Benitec Biopharma is expected to report Q4 2026 earnings before market open on September 28. Analysts forecast a loss of approximately $0.27 per share, following the company’s prior quarter result of a $0.26 per-share loss, which matched estimates.
• BNTC shares opened at $11.02, with a market capitalization of about $384 million and a 52-week trading range of $9.85 to $16.76. Analysts maintain a “Moderate Buy” consensus rating and a $24 average price target, despite mixed recent rating changes.
• Benitec is a clinical-stage biotechnology company developing DNA-directed RNA interference genetic medicines; its lead candidate, BB-301, targets the rare muscle disorder oculopharyngeal muscular dystrophy type 1.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) is expected to announce its Q4 2026 results before the market opens on Monday, September 28th. Analysts expect Benitec Biopharma to announce earnings of ($0.2686) per share for the quarter. Investors may review the information on the company's upcoming Q4 2026 earning summary page for the latest details on the call scheduled for Monday, September 14, 2026 at 4:00 PM ET.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last announced its quarterly earnings data on Monday, September 14th. The biotechnology company reported ($0.26) EPS for the quarter, meeting the consensus estimate of ($0.26). On average, analysts expect Benitec Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Benitec Biopharma Price Performance

NASDAQ BNTC opened at $11.02 on Monday. The business has a fifty day moving average price of $12.43 and a two-hundred day moving average price of $12.04. Benitec Biopharma has a fifty-two week low of $9.85 and a fifty-two week high of $16.76. The stock has a market capitalization of $384.38 million, a PE ratio of -11.24 and a beta of 0.27.

Wall Street Analysts Forecast Growth

BNTC has been the subject of a number of research analyst reports. Wall Street Zen cut Benitec Biopharma from a "hold" rating to a "sell" rating in a report on Saturday. Royal Bank Of Canada raised Benitec Biopharma to an "outperform" rating in a research note on Tuesday, September 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Benitec Biopharma in a research report on Friday, July 17th. Guggenheim cut Benitec Biopharma from a "buy" rating to a "neutral" rating in a research report on Wednesday, June 10th. Finally, Citigroup reissued a "market outperform" rating on shares of Benitec Biopharma in a research note on Tuesday, September 15th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Benitec Biopharma has a consensus rating of "Moderate Buy" and a consensus target price of $24.00.

About Benitec Biopharma

Benitec Biopharma Inc NASDAQ: BNTC is a clinical-stage biotechnology company developing genetic medicines based on DNA-directed RNA interference (ddRNAi). The company's technology is designed to enable long-lasting suppression of disease-causing genes by delivering genetic instructions that produce RNA interference molecules within targeted cells.

Benitec's lead product candidate is BB-301, an investigational gene therapy being developed for oculopharyngeal muscular dystrophy type 1 (OPMD), a rare inherited disorder that can cause progressive weakness of the muscles involved in swallowing and eye movement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.